The stock price of Argen X SE ADR (NASDAQ: ARGX) has jumped by 3.71 compared to previous close of 581.21. Despite this, the company has seen a gain of 1.44% in its stock price over the last five trading days. globenewswire.com reported 2025-03-07 that Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego, CA from April 5-9, 2025.
Is It Worth Investing in Argen X SE ADR (NASDAQ: ARGX) Right Now?
The price-to-earnings ratio for Argen X SE ADR (NASDAQ: ARGX) is 47.25x, which is above its average ratio. Moreover, the 36-month beta value for ARGX is 0.60. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ARGX is 60.44M and currently, short sellers hold a 3.30% of that float. On March 14, 2025, ARGX’s average trading volume was 272.32K shares.
ARGX’s Market Performance
The stock of Argen X SE ADR (ARGX) has seen a 1.44% increase in the past week, with a -7.13% drop in the past month, and a -1.16% fall in the past quarter. The volatility ratio for the week is 2.69%, and the volatility levels for the past 30 days are at 2.45% for ARGX. The simple moving average for the past 20 days is -2.37% for ARGX’s stock, with a 9.49% simple moving average for the past 200 days.
Analysts’ Opinion of ARGX
Wolfe Research gave a rating of “Outperform” to ARGX, setting the target price at $697 in the report published on November 12th of the previous year.
ARGX Trading at -5.33% from the 50-Day Moving Average
After a stumble in the market that brought ARGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.12% of loss for the given period.
Volatility was left at 2.45%, however, over the last 30 days, the volatility rate increased by 2.69%, as shares sank -7.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.20% lower at present.
During the last 5 trading sessions, ARGX rose by +0.99%, which changed the moving average for the period of 200-days by +63.49% in comparison to the 20-day moving average, which settled at $617.30. In addition, Argen X SE ADR saw -1.99% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ARGX
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.87 for the gross margin
The net margin for Argen X SE ADR stands at -0.05. The total capital return value is set at -0.09. Equity return is now at value -5.75, with -5.12 for asset returns.
Based on Argen X SE ADR (ARGX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -4.29. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -189.14.
Currently, EBITDA for the company is -216.02 million with net debt to EBITDA at 29.63. When we switch over and look at the enterprise to sales, we see a ratio of 15.56. The receivables turnover for the company is 3.45for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.53.
Conclusion
To wrap up, the performance of Argen X SE ADR (ARGX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
